Moderna reported a massive miss on revenue in its Q3 earnings, taking in $5 billion versus the expected $6.21 billion despite sales of the COVID-19 vaccine. The pharmaceutical giant's stock dropped sharply on the news.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.